Drug Profile
Amlodipine/losartan - GSK
Alternative Names: GSK-2944406Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihypertensives; Dihydropyridines; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in Australia (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension(In volunteers) in South Africa (PO, Tablet)
- 01 Jul 2013 GlaxoSmithKline completes a phase I trial in Hypertension (in volunteers) in South Africa (NCT01797926)